How to buy Caladrius Biosciences stock (CLBS)

Caladrius Biosciences is a biotechnology business based in the US. Caladrius Biosciences shares (CLBS) are listed on the NASDAQ and all prices are listed in US Dollars. Caladrius Biosciences employs 27 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Caladrius Biosciences stock

Buy Caladrius Biosciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Caladrius Biosciences stock price (NASDAQ: CLBS)

Use our graph to track the performance of CLBS stocks over time.

Caladrius Biosciences shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$7.17
200-day moving average more info button	$9.19
Wall St. target price	$4.50
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-0.39

Is it a good time to buy Caladrius Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Caladrius Biosciences financials

Gross profit TTM	$0
Return on assets TTM	-17.45%
Return on equity TTM	-26.31%
Profit margin	0%
Book value	$1.36
Market Capitalization more info button	$25.8 million

TTM: trailing 12 months

Caladrius Biosciences share dividends

We're not expecting Caladrius Biosciences to pay a dividend over the next 12 months.

Have Caladrius Biosciences's shares ever split?

Caladrius Biosciences's shares were split on a 1:15 basis on 14 September 2022 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Caladrius Biosciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Caladrius Biosciences shares which in turn could have impacted Caladrius Biosciences's share price.

Caladrius Biosciences share price volatility

Over the last 12 months, Caladrius Biosciences's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Caladrius Biosciences's is 0.9133. This would suggest that Caladrius Biosciences's shares are less volatile than average (for this exchange).

Caladrius Biosciences overview

Caladrius Biosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc.

Frequently asked questions

null
What percentage of Caladrius Biosciences is owned by insiders or institutions?
Currently 2.853% of Caladrius Biosciences shares are held by insiders and 19.495% by institutions. How many people work for Caladrius Biosciences?
Latest data suggests 27 work at Caladrius Biosciences. When does the fiscal year end for Caladrius Biosciences?
Caladrius Biosciences's fiscal year ends in December. Where is Caladrius Biosciences based?
Caladrius Biosciences's address is: 110 Allen Road, Basking Ridge, NJ, United States, 07920 What is Caladrius Biosciences's ISIN number?
Caladrius Biosciences's international securities identification number is: US1280582032 What is Caladrius Biosciences's CUSIP number?
Caladrius Biosciences's Committee on Uniform Securities Identification Procedures number is: 640650107